Skip to main content

BIOANALYTICIAL SYS INC. - Fundamentalanalyse - Jahresbericht / Bilanz / Geschäftsbericht

BIOANALYTICIAL SYS INC. (ISIN: US09058M1036, WKN: 923198) Kursdatum: 21.07.2017 Kurs: 1,800 USD
Beschreibung Daten
Symbol BASI
Marktkapitalisierung 14.592.600,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Biotechnologie
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet
Letztes Bilanz Update 28.12.2016

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 21.07.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-72,96 13,77 0,01% -15,34 35,28 -4,50 0,71 1,96

Firmenbeschreibung

Firmenstrategie

(a) Principles of Consolidation   The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated.

RevenueRecognitionPolicyTextBlock

 

 
(b)
 
 
Revenue Recognition
 

 

 

 

The majority of our bioanalytical and analytical research service contracts involve the development of analytical methods and the processing of bioanalytical samples for pharmaceutical companies and generally provide for a fixed fee for each sample processed. Revenue is recognized under the specific performance method of accounting and the related direct costs are recognized when services are performed. Our preclinical research service contracts generally consist of preclinical studies, and revenue is recognized under the proportional performance method of accounting. Revisions in profit estimates, if any, are reflected on a cumulative basis in the period in which such revisions become known. The establishment of contract prices and total contract costs involves estimates we make at the inception of the contract. These estimates could change during the term of the contract and impact the revenue and costs reported in the consolidated financial statements. Revisions to estimates have generally not been material. Research service contract fees received upon acceptance are deferred until earned, and classified within customer advances. Unbilled revenues represent revenues earned under contracts in advance of billings.

 

 

 

Product revenue from sales of equipment not requiring installation, testing or training is recognized upon shipment to customers. One product includes internally developed software and requires installation, testing and training, which occur concurrently. Revenue from these sales is recognized upon completion of the installation, testing and training when the services are bundled with the equipment sale.

 

SegmentReportingDisclosureTextBlock

 

 

 

 

 

 
 
 
12.
 
 
SEGMENT INFORMATION
 

 

 

 

We operate in two principal segments – contract research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. We evaluate performance and allocate resources based on these segments. Certain of our assets are not directly attributable to the Services or Products segments. These assets are grouped into the Corporate segment and include cash and cash equivalents, deferred income taxes, refundable income taxes, debt issue costs and certain other assets. We do not allocate such items to the principal segments because they are not used to evaluate their financial position. The accounting policies of these segments are the same as those described in the summary of significant accounting policies.

 

   

 
 
 
(a)
 
 
Operating Segments 
 

 

 

 

 

 

 
 
 
 
 
 
 
Years Ended September 30,
 
 
 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
2015
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Services
 
 
 
 
 
$
 
 
15,924
 
 
 
 
 
$
 
 
17,768
 
 
 
 
 
Products
 
 
 
 
 
 
 
 
4,517
 
 
 
 
 
 
 
 
4,930
 
 
 
 
 
 
 
 
 
 
 
$
 
 
20,441
 
 
 
 
 
$
 
 
22,698
 
 
 
 
 
Operating (loss) income  :
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Services
 
 
 
 
 
$
 
 
(1,576)
 
 
 
 
 
$
 
 
889
 
 
 
 
 
Products
 
 
 
 
 
 
 
 
(1,464)
 
 
 
 
 
 
 
 
20
 
 
 
 
 
 
 
 
 
 
 
$
 
 
(3,040)
 
 
 
 
 
$
 
 
909
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest Expense
 
 
 
 
 
 
 
 
(399)
 
 
 
 
 
 
 
 
(287)
 
 
 
 
 
Decrease in fair value of warrant liability
 
 
 
 
 
 
 
 
189
 
 
 
 
 
 
 
 
487
 
 
 
 
 
Other income
 
 
 
 
 
 
 
 
6
 
 
 
 
 
 
 
 
5
 
 
 
 
 
Income (loss) before income taxes
 
 
 
 
 
$
 
 
(3,244)
 
 
 
 
 
$
 
 
1,114
 
 
 
 

 

 

 

 

 

 

 

 

 
 
 
 
 
 
 
Years Ended September 30,
 
 
 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
2015
 
 
 
 
 
Identifiable assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Services
 
 
 
 
 
$
 
 
12,413
 
 
 
 
 
$
 
 
14,709
 
 
 
 
 
Products
 
 
 
 
 
 
 
 
5,562
 
 
 
 
 
 
 
 
5,821
 
 
 
 
 
Corporate
 
 
 
 
 
 
 
 
3,164
 
 
 
 
 
 
 
 
3,285
 
 
 
 
 
 
 
 
 
 
 
$
 
 
21,139
 
 
 
 
 
$
 
 
23,815
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill, net:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Services
 
 
 
 
 
$
 
 
38
 
 
 
 
 
$
 
 
1,009
 
 
 
 
 
Products
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$
 
 
38
 
 
 
 
 
$
 
 
1,009
 
 
 
 

 

 

 

 

 

EarningsPerSharePolicyTextBlock

 

 

 

 

 

 
 
 
 
 
 
 
Years Ended September 30,
 
 
 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
2015
 
 
 
 
 
Depreciation and amortization:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Services
 
 
 
 
 
$
 
 
1,242
 
 
 
 
 
$
 
 
1,228
 
 
 
 
 
Products
 
 
 
 
 
 
 
 
314
 
 
 
 
 
 
 
 
209
 
 
 
 
 
 
 
 
 
 
 
$
 
 
1,556
 
 
 
 
 
$
 
 
1,437
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Capital expenditures:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Services
 
 
 
 
 
$
 
 
945
 
 
 
 
 
$
 
 
1,073
 
 
 
5.
 
 
INCOME (LOSS) PER SHARE
 

 

 

 

We compute basic income (loss) per share using the weighted average number of common shares outstanding. The Company has two categories of dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered direct offering and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method for preferred stock and the treasury stock method for stock options, respectively. Shares issuable upon exercise of 209 vested options and 592 common shares issuable upon conversion of preferred shares were not considered in computing diluted income (loss) per share for the year ended September 30, 2016, because they were anti-dilutive.

 

 

 

The following table reconciles our computation of basic net income (loss) per share to diluted net income (loss) per share:

 

 

 

 

 
 
 
 
 
 
 
Years Ended September 30,
 
 
 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
2015
 
 
 
 
 
Basic net income (loss) per share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net (loss) income  applicable to common shareholders
 
 
 
 
 
$
 
 
(3,230)
 
 
 
 
 
$
 
 
1,099
 
 
 
 
 
Weighted average common shares outstanding
 
 
 
 
 
 
 
 
8,107
 
 
 
 
 
 
 
 
8,084
 
 
 
 
 
Basic net (loss) income per share
 
 
 
 
 
$
 
 
(0.40)
 
 
 
 
 
$
 
 
0.14
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted net income (loss) per share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net (loss) income  applicable to common shareholders
 
 
 
 
 
$
 
 
(3,230)
 
 
 
 
 
$
 
 
1,099
 
 
 
 
 
Change in fair value of warrant liability
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(487)
 
 
 
 
 
Diluted net (loss) income applicable to common shareholders
 
 
 
 
 
$
 
 
(3,230)
 
 
 
 
 
$
 
 
612
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted average common shares outstanding
 
 
 
 
 
 
 
 
8,107
 
 
 
 
 
 
 
 
8,084
 
 
 
 
 
Plus:  Incremental shares from assumed conversions:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Series A preferred shares
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
593
 
 
 
 
 
Class A warrants
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
 
 
 
 
 
Dilutive stock options/shares
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110
 
 
 
 
 
Diluted weighted average common shares outstanding
 
 
 
 
 
 
 
 
8,107
 
 
 
 
 
 
 
 
8,791
 
 
 
 
 
Diluted net (loss) income per share
 
 
 
 
 
$
 
 
(0.40)
 
 
 
 
 
$
 
 
0.07